{"name":"Repurposed Therapeutics, Inc.","slug":"repurposed-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"DPI-386 Nasal Gel","genericName":"DPI-386 Nasal Gel","slug":"dpi-386-nasal-gel","indication":"Other","status":"phase_3"},{"name":"Transdermal Scopolamine","genericName":"Transdermal Scopolamine","slug":"transdermal-scopolamine","indication":"Prevention of motion sickness","status":"marketed"},{"name":"scopolamine HBr","genericName":"scopolamine HBr","slug":"scopolamine-hbr","indication":"Motion sickness prevention","status":"phase_3"}]}],"pipeline":[{"name":"DPI-386 Nasal Gel","genericName":"DPI-386 Nasal Gel","slug":"dpi-386-nasal-gel","phase":"phase_3","mechanism":"DPI-386 is a repurposed therapeutic delivered as a nasal gel formulation, designed to provide local or systemic therapeutic effects through intranasal administration.","indications":[],"catalyst":""},{"name":"Transdermal Scopolamine","genericName":"Transdermal Scopolamine","slug":"transdermal-scopolamine","phase":"marketed","mechanism":"Transdermal scopolamine blocks muscarinic acetylcholine receptors to reduce motion sickness and nausea by decreasing vestibular sensitivity and gastric motility.","indications":["Prevention of motion sickness","Prevention of nausea and vomiting associated with travel"],"catalyst":""},{"name":"scopolamine HBr","genericName":"scopolamine HBr","slug":"scopolamine-hbr","phase":"phase_3","mechanism":"Scopolamine HBr is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea.","indications":["Motion sickness prevention","Nausea and vomiting (potentially in phase 3 context)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPcWNLUDhuMGdvdVJYdnJDM1lReVdvZklvTTAxa0lYbHRtWUxEZnB3YURSU0NoSkhrNkdHLWgtenN1aksxdWYxUndtRUhWemxOSU9lc0dsajRfaFA2N3hYalJEeURqWGxPZUJUenhuUWt5VnlrOEkwYXNURlFHWGFlRmpPS21yZjlFUmp1RjBzYi0zWThHRnFyZXlZcVp3RFJMcXpPVm9ja2lrRDJ0NTJ2dHdNWQ?oc=5","date":"2026-03-25","type":"pipeline","source":"stocktitan.net","summary":"Rare-disease push: Inhibitor Therapeutics (OTCQB: INTI) outlines BCCNS plan - stocktitan.net","headline":"Rare-disease push: Inhibitor Therapeutics (OTCQB: INTI) outlines BCCNS plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQY1JkZ21za2VsaG9reTZrbGNyeHhaVXdEY202SzdaTV91c2JMU0wtaG9ONHhiZDdKQ0dHSWxHbzhubkZteE9NcmFWSmZMalpqa24ySXZRbHhaLWV6YVM3NGFIeVI4eXZZT0hpMVRsWXVqNjZRNEZtSV9BcE9zMkVKVy0wa0xZT2tjOTdCTURLUQ?oc=5","date":"2026-02-20","type":"pipeline","source":"Pharmaceutical Technology","summary":"Syngene and VivaMed collaborate on therapeutic programmes - Pharmaceutical Technology","headline":"Syngene and VivaMed collaborate on therapeutic programmes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPcEs2WkVqNEpLTWFUaGdldFAycnMtLVhRYjcyRVlOY0oxdXdXTlNOVXlqb21TTFQyY0l5R2dqclFlYWZjUGlLRHZRWEI2NW9VOFNLRC1lSEhEeDUzNzRzeldybjFuMGRQVVYtSnV6eURLdGtCZWdtT0FqSmEyUXNiRi1RMDRhV2REYUJNNE5KQWYzNUdkTzJ6bDFOSXRWUDU3WEowanIyMWRBN1cyTEl4ai1aUUI3NEdPcW5NUFlYOG5IcHR2VzlQUWxNRHA5bFpqRmM5bDBCb1BldmtuTW0wcUphNUZTYWRhNWkyZGlFcHN1cXE2TGlfUGd0bDNUT0JLdmZyLW1CR2VRRjdWZTFBd0N5UGJLSnlLeE5QXzdjYWVBQTJSS2Q5d3hqWkRyUQ?oc=5","date":"2026-02-19","type":"deal","source":"Business Wire","summary":"VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure - Business Wire","headline":"VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Glob","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbjRqeVFJazA4RlI4cC1QaXhwZHdoNjFIcThCckNlZ2xfc2NrLXp0SnhodmdkUFFZN05EWVJSbll2VDl5RUNEVjduWmVNOXlqV1hBM3R3OHBSZWp5M09pdjlFM2lYRV92aHlmNmNoMVBKYzhaNW5GTzhNRzNTSHdFaC1kb1FWMl92?oc=5","date":"2026-02-02","type":"pipeline","source":"Fierce Pharma","summary":"Top 10 most anticipated drug launches of 2026 - Fierce Pharma","headline":"Top 10 most anticipated drug launches of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE13ZnR2bzdYbzIzN3FIVmp3cXYyTlpEM19wRHBCVE5rdy12Qk9xM3JJb2l6VWI2TnRTb0lJX2FFeTRQYkp0ZDFmWG1RMjV2ZENhRkRvRGI2NEZMc2VlcDhr?oc=5","date":"2026-01-08","type":"pipeline","source":"Nature","summary":"Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation - Nature","headline":"Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOZV9lN1dJd1JrX05BWi05R0x1NEdZcUdFU01ZZTd6bDQyQzk4RzBZWThpQXRHNDV4NnhnNkg5alptanpIcjVfcmpqV2s3MlNQQ3YwWkJxQmpxanRFWnc4UU5fT0NtMTQxVEdJYnBuQ1AwRFpQd2dtSlhHcGloTTZFNU1xeE9sR0tNOWN4dUFreFBoOGtSQng0dVo1Ny1XcDRwN1VDQUh1RFdZdWtueTlHVWljRGNGNDRHY2lPNDFmYWxjRkFUTGpMczRacnYzVmstUndVUjlSV013ZUVNZkF5bkZVUHlQZmxya2VsQUFnLXFCMzFPSExyZG5SbGlQcmQyNjBySzZkalRhYlYwUkFQUHpXakJJYnEyVkVsdmtDSnh5Zw?oc=5","date":"2026-01-07","type":"pipeline","source":"GlobeNewswire","summary":"Artificial Intelligence in Drug Repurposing Global Market - GlobeNewswire","headline":"Artificial Intelligence in Drug Repurposing Global Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZWVycEtvaGt5dWlMMF9DNGtwSUh5N0IyX0N2YTRzSnFTVFE2T2NkSkxsaEVvVkU4MV9XdkFuOFIwSHRPUDhLUnd6QUFoQ2JGaThBSTNyTnNXTnI0VVVmWXBxbk9LZlhzM2RDT0NHU01jQlQtMGpLLTd2cEVwNEVHS0U0NjgtQkxBZk1jVkFGNVhHdzFk?oc=5","date":"2025-05-28","type":"regulatory","source":"Yahoo Finance","summary":"Drug Repurposing Strategic Research Business Report 2025: Global Market to Reach $37.3 Billion by 2030 - Surging Demand for Personalized Therapies Promotes Indication-Specific Repurposing Approaches -","headline":"Drug Repurposing Strategic Research Business Report 2025: Global Market to Reach $37.3 Billion by 2030 - Surging Demand ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQd2E3c2t1a29vc3QxZlFqUEtqZG41NEdKNk1EdDVFdlluSXpfMWIzMFlnRV91d1dacVpOMWswcXJnZkhXZE9SZTZjU1c0SmpGSUtPQXZfWTFHMW5EMmRIX3hDWVlfVmFRSDFYbjdtQUNGR250d3B3aFRyWlVlLURQR3dNTklENVRSTFcwVEkxdUpLbzRDalV2RQ?oc=5","date":"2025-04-28","type":"pipeline","source":"Yahoo Finance","summary":"Qualthera Health Corporation Launches Qualthera Pharmaceuticals Ltd. Co., a New R&D Subsidiary Focused on Drug Repurposing and Innovative Delivery - Yahoo Finance","headline":"Qualthera Health Corporation Launches Qualthera Pharmaceuticals Ltd. Co., a New R&D Subsidiary Focused on Drug Repurposi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBPa1hVSnFIRmd4WXE5aGp3S2t0NnZ2a25QeGVWMVdPZUMyLUlyUlR4eFd4RGgzekxQT1NDRzlTblpKSkk5Y19tM3g4b0VYb0ROZ1NkcXVOa2dxRVlENmZWSjVzY0hjdHFCRmJHOTJabw?oc=5","date":"2025-01-23","type":"pipeline","source":"Wiley Online Library","summary":"Drug Repurposing: Opportunities with Challenges: Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library","headline":"Drug Repurposing: Opportunities with Challenges: Journal of Clinical Pharmacy and Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQZGliZU5TcGxoOHNOWU5YM3gyVGc4OWlkR1dfc1Fkdk5XUDVaTkY2MHBnek1YQlpZY3VyVVFtTzJteE5uMmJxODFUN2JLU25MR3ZaSW4yVjdfNmJrQm92YzZpTVhOczN0V19EWnVwc1BUSEFSVlVJTkdCcElEajYwQmgtejV1dVU?oc=5","date":"2024-08-03","type":"pipeline","source":"Business North Carolina","summary":"North Carolina pharma company being sold for $525 million - Business North Carolina","headline":"North Carolina pharma company being sold for $525 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxON2RBUmRIazl6cVA0SUdJWXVwdG9VR2ZiVjI3TjBGX2RMUGtUNGpsbXE4aGc1czA4ckRtQmZiNXc0MkE3MUs3T2psZHljcFdxR253eHdCY1V5Q0VreHY2Wkh5SWd2WFNVcFZ6OE9sdGNLbm9HdDlUbVc1NFpGM21qMWtfaHU4Q0JwWXM3SnhudUc1OXBpMlI3YW1QNWtQNVR1ZjQzeGxHUXhMdm9LaXJFY0xlU3VCRktWWWk0QV9RZXQwdTA1dXJhZjBuNWpvem8?oc=5","date":"2024-06-10","type":"pipeline","source":"Inside Precision Medicine","summary":"The Pharma Phoenix: BioXcel Therapeutics Uses AI to Repurpose Shelved Drugs - Inside Precision Medicine","headline":"The Pharma Phoenix: BioXcel Therapeutics Uses AI to Repurpose Shelved Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQVXl3dWluaV9keW5sR19XVVlnUjl6VktfdXhIN21rZjE4elNDbldDMERQNmQtRUNJRWtfbHBWMm1sUzVmQkdlWUJKR2ZxR0twTDIwaXpoRGRGU25aT3dzQjRoMkQwVUhCZGw3QVZTR0JuNVlPUFJsYUk3OE9aOXFTa2NxZzl0cGlZNTM3ell5Zi0xRnNuN3lLcEh6MmFYNnZJYlNXMDlya3c0RFY3dWo0MU1OMHphdndZb2tsRk84Nzgtalp0cm40ZnNxcUtqVW1m?oc=5","date":"2024-01-09","type":"pipeline","source":"McKinsey & Company","summary":"Generative AI in the pharmaceutical industry: Moving from hype to reality - McKinsey & Company","headline":"Generative AI in the pharmaceutical industry: Moving from hype to reality - McKinsey & Company","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}